CFTR and cystic fibrosis: To address the limitations of lumacaftor in treating certain CF patients, including variable responses, limited efficacy on lung function, drug–drug interactions, adverse effects, and poor tolerability, extensive medicinal chemistry optimizations led to the development of the next-generation CFTR corrector tezacaftor (VX-661) [103].